Last reviewed 2026-05-25 · How we verify

Nixyn (ISONIXIN)

Phase 2 active Small molecule ✓ Verified May 2026

Nixyn (generic name: ISONIXIN) is a isonixin drug. It is currently in Phase 2 development.

Nixyn works by interacting with a specific target in the body, although the exact mechanism is not yet understood.

Nixyn is a small molecule modality. It is also known by the synonyms 2-HYDROXY-2',6'-NICOTINOXYLIDIDE, ISONIXIN, ISONIXINE, ISONIXINO, and NIXYN HERMES.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ISONIXIN
Drug class	isonixin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of Nixyn like a key that fits into a lock in the body. When it binds to its target, it can either block or enhance the activity of that target, leading to changes in the body's function. However, the exact details of how Nixyn interacts with its target are still being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nixyn CI brief — competitive landscape report
Nixyn updates RSS · CI watch RSS

Frequently asked questions about Nixyn

What is Nixyn?

Nixyn (ISONIXIN) is a isonixin drug.

How does Nixyn work?

Nixyn works by interacting with a specific target in the body, although the exact mechanism is not yet understood.

What is the generic name of Nixyn?

ISONIXIN is the generic (nonproprietary) name of Nixyn.

What drug class is Nixyn in?

Nixyn belongs to the isonixin class. See all isonixin drugs at /class/isonixin.

What development phase is Nixyn in?

Nixyn is in Phase 2.

Drug class: All isonixin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing